US 11,717,690 B2
System for Brugada syndrome presence-based electrical therapeutic stimulation delivery
Daniel Felipe Ortega, San Fernando (AR); and Luis Dante Barja, Escobar (AR)
Assigned to NewStim, Inc., La Lucila (AR)
Filed by NewStim, Inc., La Lucila (AR)
Filed on Jun. 11, 2021, as Appl. No. 17/346,120.
Application 17/346,120 is a continuation of application No. 16/459,424, filed on Jul. 1, 2019, granted, now 11,033,744, issued on Jun. 15, 2021.
Application 16/459,424 is a continuation of application No. 15/474,950, filed on Mar. 30, 2017, granted, now 10,335,600, issued on Jul. 2, 2019.
Prior Publication US 2022/0395694 A1, Dec. 15, 2022
Prior Publication US 2023/0103279 A9, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/362 (2006.01); A61N 1/05 (2006.01); A61N 1/375 (2006.01); G16H 40/67 (2018.01); A61N 1/372 (2006.01)
CPC A61N 1/37512 (2017.08) [A61N 1/0595 (2013.01); A61N 1/37217 (2013.01); G16H 40/67 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A system for Brugada syndrome presence-based electrical therapeutic stimulation delivery comprising:
a cardiac pacing device comprising a pulse generator and a pair of pacing electrodes electrically coupled to the pulse generator via an endocardial lead and positioned in one of a region near the His bundle and a para-Hisian region of a patient's heart, the pulse generator configured to deliver electrical therapeutic stimulation through the pair of pacing electrodes substantially coincident to propagation of an activation wave front proceeding from the atrioventricular node of the patient's heart; and
a diagnostic module operatively coupled to the pulse generator and configured to sense via one or more sensing electrodes physiology associated with a presence of Brugada syndrome in the patient, the diagnostic module further configured to control the pulse generator in delivering the electrical therapeutic stimulation in response to the presence of the Brugada syndrome, wherein the physiology associated with the presence of Brugada syndrome comprises a QRS duration in a lead V2 longer than 90 msec and one of an inferolateral J wave and a horizontal ST segment morphology following a J wave.